{"ticker": {"uuid": "1e14fcdc-fe5f-4434-aa02-d06cd5381218", "symbol": "SPRY", "name": "ARS Pharmaceuticals, Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "ARS Pharmaceuticals (NASDAQ: SPRY) reports board resignation and CMO exit", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPbzB4Qi1zazR4d19kVkJrUXRGeVRRRFAxS0tXeDB4Rm0tOGduS3h0TnFNWUZOTDRkc0JNWUVrVnF6OWFlZ3NveXl4ZjFOUHY2bEhQMjVxbHFYRk5Xa19NcllrNmJfeUJ5NmRIT3lJQVN3a3ZFTVhrVWZBeEJqdU9SampCb3lKdDdISDJFdHYzR0RRTFhjTVlPcHNfaUNmaTNwNUhvTUpIWlRsSWhTZ00wa3pn?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-17T20:02:46+00:00", "published_display": "17 Jul 2026 20:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY", "summary": "Pomerantz LLP is investigating ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) on behalf of investors following a significant stock price drop. The investigation concerns potential securities fraud or unlawful business practices after the company disclosed that its product, neffy\u00ae (epin", "url": "https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-ars-pharmaceuticals-inc---spry-302826230.html", "source_name": "PR Newswire", "published_at": "2026-07-16T14:12:08", "published_display": "16 Jul 2026 14:12", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Millennium group discloses ARS Pharmaceuticals (SPRY) ownership below 5%", "summary": "Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed an Amendment No. 2 to a Schedule 13G regarding their beneficial ownership of ARS Pharmaceuticals, Inc. common stock. The filing indicates that Integ", "url": "https://www.stocktitan.net/sec-filings/SPRY/schedule-13g-a-ars-pharmaceuticals-inc-amended-passive-investment-dis-efa3fbd037bc.html", "source_name": "Stock Titan", "published_at": "2026-07-14T22:09:49", "published_display": "14 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "What's Going on With ARS Pharma Stock Thursday? - ARS Pharmaceuticals (NASDAQ:SPRY)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNSGlXWkxYMzVvakVLNTFPeFJCYTR0YUtnaEMxREVSWl9xNzI2X1N4X0tnZ1JYRkhiNHFBOHJueVlNa2MzWXJ0SkFvRTZpbklkcElaaHh4UWdwOGRzYXA0SDk1SXlGZkJOc0tfcE41UGtJNTREQUN6XzV4STgtMXlFY2tZYlFwSXJKc2tldVBxQW14VE0xSmFhWUJxQ3B5SzV6Z1U1c1BzSQ?oc=5", "source_name": "Benzinga", "published_at": "2026-07-09T17:37:56+00:00", "published_display": "09 Jul 2026 17:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARS Pharmaceuticals, Inc. (SPRY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) following a significant drop in its share price. This investigation was prompted by the company's disclosure that its flagship product, Neffy\u00ae, did not receive ant", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/ars-pharmaceuticals-inc.-spry-investigation-bronstein-gewirtz-an-1183940", "source_name": "ACCESS Newswire", "published_at": "2026-07-08T18:11:47", "published_display": "08 Jul 2026 18:11", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARS Pharmaceuticals Announces CEO Succession", "summary": "ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) has announced a CEO succession, with co-founder Richard Lowenthal transitioning out of his role. Donn Casale, previously President, has been appointed as the new CEO and Director, effective July 7, 2026. The company expressed gratitude for", "url": "https://www.globenewswire.com/news-release/2026/07/07/3323647/0/en/ars-pharmaceuticals-announces-ceo-succession.html", "source_name": "GlobeNewswire", "published_at": "2026-07-08T09:11:47", "published_display": "08 Jul 2026 09:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARS Pharmaceuticals names Donn Casale as new CEO", "summary": "ARS Pharmaceuticals (NASDAQ:SPRY) has announced that co-founder and CEO Richard Lowenthal has stepped down, with Donn Casale appointed as the new CEO. Casale, formerly President, brings over 25 years of biopharmaceutical leadership experience, and is tasked with growing the neffy", "url": "https://www.investing.com/news/company-news/ars-pharmaceuticals-names-donn-casale-as-new-ceo-93CH-4780148", "source_name": "Investing.com", "published_at": "2026-07-07T22:09:28", "published_display": "07 Jul 2026 22:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARS Pharmaceuticals Appoints Donn Casale CEO, Succeeds Co-Founder Richard Lowenthal", "summary": "ARS Pharmaceuticals, Inc. has announced a leadership transition, with co-founder Richard Lowenthal stepping down as CEO after over a decade to be succeeded by Donn Casale, effective July 7, 2026. Casale, previously the company's President, brings over 25 years of biopharmaceutica", "url": "https://www.quiverquant.com/news/ARS+Pharmaceuticals+Appoints+Donn+Casale+CEO%2C+Succeeds+Co-Founder+Richard+Lowenthal", "source_name": "Quiver Quantitative", "published_at": "2026-07-07T20:41:00", "published_display": "07 Jul 2026 20:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARS Pharmaceuticals taps Donn Casale as CEO after Lowenthal exit", "summary": "ARS Pharmaceuticals (Nasdaq: SPRY) announced that co-founder and CEO Richard Lowenthal ceased serving as an employee and officer on July 6, 2026. Donn Casale, previously President, has been appointed CEO and Director effective July 7, 2026. Casale brings over 25 years of commerci", "url": "https://www.stocktitan.net/news/SPRY/ars-pharmaceuticals-announces-ceo-twg35jyvnkw8.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:29:55", "published_display": "07 Jul 2026 20:29", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARS Pharmaceuticals, Inc. Announces Appointment of Donn Casale as Director, Effective July 7, 2026", "summary": "ARS Pharmaceuticals, Inc. announced the appointment of Donn Casale, currently President, as a Director, effective July 7, 2026. Casale brings over 25 years of biopharmaceutical experience, with a strong background in commercial leadership and scaling innovative products. His prev", "url": "https://www.marketscreener.com/news/ars-pharmaceuticals-inc-announces-appointment-of-donn-casale-as-director-effective-july-7-2026-ce7f5ed8df8ef726", "source_name": "www.marketscreener.com", "published_at": "2026-07-07T20:09:28", "published_display": "07 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating ARS Pharmaceuticals, Inc. (SPRY) And Encourages Stockholders to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against ARS Pharmaceuticals, Inc. (SPRY) following a significant stock drop. The investigation stems from the company's disclosure that its flagship product, Neffy\u00ae, received no new commercial formulary addition", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-ars-pharmace-1183936", "source_name": "ACCESS Newswire", "published_at": "2026-07-04T07:40:26", "published_display": "04 Jul 2026 07:40", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ARS Pharmaceuticals, Inc. (ARS) and Encourages Stockholders to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into ARS Pharmaceuticals, Inc. (ARS) following a sharp drop in its share price. This investigation stems from the disclosure that Neffy\u00ae, ARS's epinephrine nasal spray, received no new commercial formulary additions", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1183934", "source_name": "ACCESS Newswire", "published_at": "2026-07-01T18:40:58", "published_display": "01 Jul 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARS Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of ARS Pharmaceuticals (SPRY)", "summary": "Levi & Korsinsky, LLP has initiated an investigation into ARS Pharmaceuticals (NASDAQ: SPRY) following a significant drop in its stock price. The investigation stems from the company's disclosure that its flagship product, Neffy\u00ae, failed to secure new commercial formulary additio", "url": "https://www.prnewswire.com/news-releases/ars-pharmaceuticals-investigation-initiated-levi--korsinsky-investigates-the-officers-and-directors-of-ars-pharmaceuticals-spry-302813390.html", "source_name": "PR Newswire", "published_at": "2026-06-29T17:40:24", "published_display": "29 Jun 2026 17:40", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 2000 Growth-Defensive Index", "summary": "ARS Pharmaceuticals, Inc. (NasdaqGM:SPRY) has been removed from the Russell 2000 Growth-Defensive Index. The company is a biopharmaceutical firm focused on treatments for allergic reactions and is commercializing neffy, an epinephrine nasal spray approved in several regions for e", "url": "https://www.marketscreener.com/news/ars-pharmaceuticals-inc-nasdaqgm-spry-dropped-from-russell-2000-growth-defensive-index-ce7f5fdfde81f025", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T06:38:57", "published_display": "29 Jun 2026 06:38", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SPRY Investors Have Opportunity to Join ARS Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm", "summary": "The Schall Law Firm has launched an investigation into ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) following a significant drop in its stock price. This investigation focuses on potential securities law violations after the company's flagship product, Neffy, failed to secure new for", "url": "https://www.businesswire.com/news/home/20260628169359/en/SPRY-Investors-Have-Opportunity-to-Join-ARS-Pharmaceuticals-Inc.-Fraud-Investigation-with-the-Schall-Law-Firm", "source_name": "Business Wire", "published_at": "2026-06-28T16:10:11", "published_display": "28 Jun 2026 16:10", "sentiment": "negative", "sentiment_pct": 8, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of ARS Pharmaceuticals, Inc. \u2013 NASDAQ:SPRY", "summary": "This article provides a financial data point for ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), specifically its price-to-earnings forward ratio. It notes that the market is closed and there are no trades, and the information is presented without specific values. The page primarily co", "url": "https://www.tradingview.com/symbols/NASDAQ-SPRY/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T05:40:45", "published_display": "27 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of ARS Pharmaceuticals, Inc. \u2013 BOATS:SPRY", "summary": "This article focuses on the enterprise value to revenue forward for ARS Pharmaceuticals, Inc. (SPRY) as monitored by the Blue Ocean Alternative Trade System (BOATS). It presents financial data within the TradingView platform, specifically under the \"Financials\" section for the co", "url": "https://www.tradingview.com/symbols/BOATS-SPRY/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T04:40:45", "published_display": "27 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARS Pharmaceuticals (NASDAQ: SPRY) grants 30,000 options to RA Capital-linked director", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPOHZJbF84bnZmUEtpc3Bld2oyazEzVlRwNzB5X0JqSVBiMmlvTXEwWE9HYk1nUmpFUFpLMllSOFk5MmtHbTVfdENEWkV4eTBObmZyLU9LMGhETEZ6RGNaTWVqQ1hYUlNLQUYwXzVBaThLdGtTWHhvSHFNcnZQVjYzbWE5djNOZ1Ezb3FEYU4yMXJ5SnVKekFXb3A3bDdPME01enJhbENfVHZoQUpMclNjcTgxWGxqZUhr?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPSGdIQWcyZVlqc3gxRE8yX2Z6dGlnSkFmdko4WkVwLXBnWU1kM0Jobmp2MER0R1RNSXBxc1U0TDhGdnpUVWlsMDJYR1hMOXZOYlQyRldROWhwcmtRNzhmT1BFR1gtZXlmUjFxZG5vak9pcENBQTl1NF9FWmEtMUZCYlJEMW9qUTJhT3JOZHFVX2xzbmNHZzlEQ3RORDNON1FBQlNZ?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ARS Pharmaceuticals, Inc. (SPRY) Soars 7.1%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPdVlMeHVZMHVrdDdDVUs1QXoyb0VFalVHbndvSG5JZEJ5NmUteVVscFVUYXhwLUV5YmR2NzhMSnd3NUs2VVdRWC12elR1bWcySnBZYm5reEtvRFN1T0NmQ1o2d3VLQnA2RkJKbEtNRXFVdnhXakZyQVlwSjZ3WGx1ZlY3aWZfbEMwSEc3bmQtWnFiTzhSeHpiYUx3WkM1VEtv?oc=5", "source_name": "Market source", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Catapults 25% Though Its Price And Business Still Lag The Industry", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-10T08:00:00+00:00", "published_display": "10 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARS Pharmaceuticals (NASDAQ:SPRY) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-15T07:00:00+00:00", "published_display": "15 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "ARS Pharmaceuticals (NASDAQ: SPRY) reports board resignation and CMO exit", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPbzB4Qi1zazR4d19kVkJrUXRGeVRRRFAxS0tXeDB4Rm0tOGduS3h0TnFNWUZOTDRkc0JNWUVrVnF6OWFlZ3NveXl4ZjFOUHY2bEhQMjVxbHFYRk5Xa19NcllrNmJfeUJ5NmRIT3lJQVN3a3ZFTVhrVWZBeEJqdU9SampCb3lKdDdISDJFdHYzR0RRTFhjTVlPcHNfaUNmaTNwNUhvTUpIWlRsSWhTZ00wa3pn?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-17T20:02:46+00:00", "published_display": "17 Jul 2026 20:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY", "summary": "Pomerantz LLP is investigating ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) on behalf of investors following a significant stock price drop. The investigation concerns potential securities fraud or unlawful business practices after the company disclosed that its product, neffy\u00ae (epin", "url": "https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-ars-pharmaceuticals-inc---spry-302826230.html", "source_name": "PR Newswire", "published_at": "2026-07-16T14:12:08", "published_display": "16 Jul 2026 14:12", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Millennium group discloses ARS Pharmaceuticals (SPRY) ownership below 5%", "summary": "Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed an Amendment No. 2 to a Schedule 13G regarding their beneficial ownership of ARS Pharmaceuticals, Inc. common stock. The filing indicates that Integ", "url": "https://www.stocktitan.net/sec-filings/SPRY/schedule-13g-a-ars-pharmaceuticals-inc-amended-passive-investment-dis-efa3fbd037bc.html", "source_name": "Stock Titan", "published_at": "2026-07-14T22:09:49", "published_display": "14 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What's Going on With ARS Pharma Stock Thursday? - ARS Pharmaceuticals (NASDAQ:SPRY)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNSGlXWkxYMzVvakVLNTFPeFJCYTR0YUtnaEMxREVSWl9xNzI2X1N4X0tnZ1JYRkhiNHFBOHJueVlNa2MzWXJ0SkFvRTZpbklkcElaaHh4UWdwOGRzYXA0SDk1SXlGZkJOc0tfcE41UGtJNTREQUN6XzV4STgtMXlFY2tZYlFwSXJKc2tldVBxQW14VE0xSmFhWUJxQ3B5SzV6Z1U1c1BzSQ?oc=5", "source_name": "Benzinga", "published_at": "2026-07-09T17:37:56+00:00", "published_display": "09 Jul 2026 17:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARS Pharmaceuticals, Inc. (SPRY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) following a significant drop in its share price. This investigation was prompted by the company's disclosure that its flagship product, Neffy\u00ae, did not receive ant", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/ars-pharmaceuticals-inc.-spry-investigation-bronstein-gewirtz-an-1183940", "source_name": "ACCESS Newswire", "published_at": "2026-07-08T18:11:47", "published_display": "08 Jul 2026 18:11", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARS Pharmaceuticals Announces CEO Succession", "summary": "ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) has announced a CEO succession, with co-founder Richard Lowenthal transitioning out of his role. Donn Casale, previously President, has been appointed as the new CEO and Director, effective July 7, 2026. The company expressed gratitude for", "url": "https://www.globenewswire.com/news-release/2026/07/07/3323647/0/en/ars-pharmaceuticals-announces-ceo-succession.html", "source_name": "GlobeNewswire", "published_at": "2026-07-08T09:11:47", "published_display": "08 Jul 2026 09:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARS Pharmaceuticals names Donn Casale as new CEO", "summary": "ARS Pharmaceuticals (NASDAQ:SPRY) has announced that co-founder and CEO Richard Lowenthal has stepped down, with Donn Casale appointed as the new CEO. Casale, formerly President, brings over 25 years of biopharmaceutical leadership experience, and is tasked with growing the neffy", "url": "https://www.investing.com/news/company-news/ars-pharmaceuticals-names-donn-casale-as-new-ceo-93CH-4780148", "source_name": "Investing.com", "published_at": "2026-07-07T22:09:28", "published_display": "07 Jul 2026 22:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARS Pharmaceuticals Appoints Donn Casale CEO, Succeeds Co-Founder Richard Lowenthal", "summary": "ARS Pharmaceuticals, Inc. has announced a leadership transition, with co-founder Richard Lowenthal stepping down as CEO after over a decade to be succeeded by Donn Casale, effective July 7, 2026. Casale, previously the company's President, brings over 25 years of biopharmaceutica", "url": "https://www.quiverquant.com/news/ARS+Pharmaceuticals+Appoints+Donn+Casale+CEO%2C+Succeeds+Co-Founder+Richard+Lowenthal", "source_name": "Quiver Quantitative", "published_at": "2026-07-07T20:41:00", "published_display": "07 Jul 2026 20:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARS Pharmaceuticals taps Donn Casale as CEO after Lowenthal exit", "summary": "ARS Pharmaceuticals (Nasdaq: SPRY) announced that co-founder and CEO Richard Lowenthal ceased serving as an employee and officer on July 6, 2026. Donn Casale, previously President, has been appointed CEO and Director effective July 7, 2026. Casale brings over 25 years of commerci", "url": "https://www.stocktitan.net/news/SPRY/ars-pharmaceuticals-announces-ceo-twg35jyvnkw8.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:29:55", "published_display": "07 Jul 2026 20:29", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARS Pharmaceuticals, Inc. Announces Appointment of Donn Casale as Director, Effective July 7, 2026", "summary": "ARS Pharmaceuticals, Inc. announced the appointment of Donn Casale, currently President, as a Director, effective July 7, 2026. Casale brings over 25 years of biopharmaceutical experience, with a strong background in commercial leadership and scaling innovative products. His prev", "url": "https://www.marketscreener.com/news/ars-pharmaceuticals-inc-announces-appointment-of-donn-casale-as-director-effective-july-7-2026-ce7f5ed8df8ef726", "source_name": "www.marketscreener.com", "published_at": "2026-07-07T20:09:28", "published_display": "07 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating ARS Pharmaceuticals, Inc. (SPRY) And Encourages Stockholders to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against ARS Pharmaceuticals, Inc. (SPRY) following a significant stock drop. The investigation stems from the company's disclosure that its flagship product, Neffy\u00ae, received no new commercial formulary addition", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-ars-pharmace-1183936", "source_name": "ACCESS Newswire", "published_at": "2026-07-04T07:40:26", "published_display": "04 Jul 2026 07:40", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ARS Pharmaceuticals, Inc. (ARS) and Encourages Stockholders to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into ARS Pharmaceuticals, Inc. (ARS) following a sharp drop in its share price. This investigation stems from the disclosure that Neffy\u00ae, ARS's epinephrine nasal spray, received no new commercial formulary additions", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1183934", "source_name": "ACCESS Newswire", "published_at": "2026-07-01T18:40:58", "published_display": "01 Jul 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARS Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of ARS Pharmaceuticals (SPRY)", "summary": "Levi & Korsinsky, LLP has initiated an investigation into ARS Pharmaceuticals (NASDAQ: SPRY) following a significant drop in its stock price. The investigation stems from the company's disclosure that its flagship product, Neffy\u00ae, failed to secure new commercial formulary additio", "url": "https://www.prnewswire.com/news-releases/ars-pharmaceuticals-investigation-initiated-levi--korsinsky-investigates-the-officers-and-directors-of-ars-pharmaceuticals-spry-302813390.html", "source_name": "PR Newswire", "published_at": "2026-06-29T17:40:24", "published_display": "29 Jun 2026 17:40", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 2000 Growth-Defensive Index", "summary": "ARS Pharmaceuticals, Inc. (NasdaqGM:SPRY) has been removed from the Russell 2000 Growth-Defensive Index. The company is a biopharmaceutical firm focused on treatments for allergic reactions and is commercializing neffy, an epinephrine nasal spray approved in several regions for e", "url": "https://www.marketscreener.com/news/ars-pharmaceuticals-inc-nasdaqgm-spry-dropped-from-russell-2000-growth-defensive-index-ce7f5fdfde81f025", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T06:38:57", "published_display": "29 Jun 2026 06:38", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SPRY Investors Have Opportunity to Join ARS Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm", "summary": "The Schall Law Firm has launched an investigation into ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) following a significant drop in its stock price. This investigation focuses on potential securities law violations after the company's flagship product, Neffy, failed to secure new for", "url": "https://www.businesswire.com/news/home/20260628169359/en/SPRY-Investors-Have-Opportunity-to-Join-ARS-Pharmaceuticals-Inc.-Fraud-Investigation-with-the-Schall-Law-Firm", "source_name": "Business Wire", "published_at": "2026-06-28T16:10:11", "published_display": "28 Jun 2026 16:10", "sentiment": "negative", "sentiment_pct": 8, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of ARS Pharmaceuticals, Inc. \u2013 NASDAQ:SPRY", "summary": "This article provides a financial data point for ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), specifically its price-to-earnings forward ratio. It notes that the market is closed and there are no trades, and the information is presented without specific values. The page primarily co", "url": "https://www.tradingview.com/symbols/NASDAQ-SPRY/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T05:40:45", "published_display": "27 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of ARS Pharmaceuticals, Inc. \u2013 BOATS:SPRY", "summary": "This article focuses on the enterprise value to revenue forward for ARS Pharmaceuticals, Inc. (SPRY) as monitored by the Blue Ocean Alternative Trade System (BOATS). It presents financial data within the TradingView platform, specifically under the \"Financials\" section for the co", "url": "https://www.tradingview.com/symbols/BOATS-SPRY/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T04:40:45", "published_display": "27 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARS Pharmaceuticals (NASDAQ: SPRY) grants 30,000 options to RA Capital-linked director", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPOHZJbF84bnZmUEtpc3Bld2oyazEzVlRwNzB5X0JqSVBiMmlvTXEwWE9HYk1nUmpFUFpLMllSOFk5MmtHbTVfdENEWkV4eTBObmZyLU9LMGhETEZ6RGNaTWVqQ1hYUlNLQUYwXzVBaThLdGtTWHhvSHFNcnZQVjYzbWE5djNOZ1Ezb3FEYU4yMXJ5SnVKekFXb3A3bDdPME01enJhbENfVHZoQUpMclNjcTgxWGxqZUhr?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPSGdIQWcyZVlqc3gxRE8yX2Z6dGlnSkFmdko4WkVwLXBnWU1kM0Jobmp2MER0R1RNSXBxc1U0TDhGdnpUVWlsMDJYR1hMOXZOYlQyRldROWhwcmtRNzhmT1BFR1gtZXlmUjFxZG5vak9pcENBQTl1NF9FWmEtMUZCYlJEMW9qUTJhT3JOZHFVX2xzbmNHZzlEQ3RORDNON1FBQlNZ?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARS Pharmaceuticals, Inc. (SPRY) Soars 7.1%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPdVlMeHVZMHVrdDdDVUs1QXoyb0VFalVHbndvSG5JZEJ5NmUteVVscFVUYXhwLUV5YmR2NzhMSnd3NUs2VVdRWC12elR1bWcySnBZYm5reEtvRFN1T0NmQ1o2d3VLQnA2RkJKbEtNRXFVdnhXakZyQVlwSjZ3WGx1ZlY3aWZfbEMwSEc3bmQtWnFiTzhSeHpiYUx3WkM1VEtv?oc=5", "source_name": "Market source", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Catapults 25% Though Its Price And Business Still Lag The Industry", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-10T08:00:00+00:00", "published_display": "10 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARS Pharmaceuticals (NASDAQ:SPRY) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-15T07:00:00+00:00", "published_display": "15 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 97, "total_relevant": 31, "sentiment_summary": {"positive": 6, "negative": 8, "neutral": 17, "score": 46, "total": 31, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 75, "events": [{"event": "general", "label": "Market update", "weight": 6.6, "count": 12}, {"event": "earnings", "label": "Earnings", "weight": 5.36, "count": 12}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 3.85, "count": 7}], "positive_events": 6, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 7.94, "latest_week": "2026-07-10", "one_week_move": -7.2, "four_week_move": -18.6, "twelve_week_move": -2.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.618329, "market_dynamics_buy_signal": false, "relative_strength": -34.001208, "fair_value_gap": -22.1, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 54.5712, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-7.2% over one week, -18.6% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 8}, {"label": "Stock Titan", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "ACCESS Newswire", "count": 3}, {"label": "TradingView", "count": 3}, {"label": "PR Newswire", "count": 2}, {"label": "www.marketscreener.com", "count": 2}, {"label": "Benzinga", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 22}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 12}, {"label": "Earnings", "count": 12}, {"label": "Regulatory and legal", "count": 7}]}, "insights": [{"label": "Weighted tone", "value": "46/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "22", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-7.2% over one week, -18.6% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "ARS Pharmaceuticals (NASDAQ: SPRY) reports board resignation and CMO exit"}], "updated_at": "2026-07-17T22:39:14.243930+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}